Nuclear factor-κ13 in development, prevention, and therapy of cancer

被引:255
作者
Van Waes, Carter
机构
[1] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Bethesda, MD 20892 USA
[2] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-06-2221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear factor-kappa B (NF-kappa B) is a signal transcription factor that has emerged as an important modulator of altered gene programs and malignant phenotype in development of cancer. Major carcinogens and oncogenic viruses induce NF-kappa B activation, and a variety of subsequent oncogenic events contribute to a progressive increase in constitutive NF-kappa B activation as an important common pathway in most forms of cancer. NF-kappa B target genes promote tumor cell proliferation, survival, migration, inflammation, and angiogenesis. Inhibition of NF-kappa B has been found to be an important mechanism of action of steroids, nonsteroidal anti-inflammatory drugs, and natural and synthetic compounds that show therapeutic and preventive activity. Newer agents targeting the proteasome, inhibitor-kappa B kinase, and other upstream kinases involved in NF-kappa B activation have shown anticancer activity in clinical or preclinical studies.
引用
收藏
页码:1076 / 1082
页数:7
相关论文
共 100 条
[31]  
Guttridge DC, 1999, MOL CELL BIOL, V19, P5785
[32]   Signaling to NF-κB [J].
Hayden, MS ;
Ghosh, S .
GENES & DEVELOPMENT, 2004, 18 (18) :2195-2224
[33]   NF-κB as a therapeutic target in multiple myeloma [J].
Hideshima, T ;
Chauhan, D ;
Richardson, P ;
Mitsiades, C ;
Mitsiades, N ;
Hayashi, T ;
Munshi, N ;
Dang, L ;
Castro, A ;
Palombella, V ;
Adams, J ;
Anderson, KC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) :16639-16647
[34]   Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity [J].
Hinz, M ;
Lemke, P ;
Anagnostopoulos, I ;
Hacker, C ;
Krappmann, D ;
Mathas, S ;
Dörken, B ;
Zenke, M ;
Stein, H ;
Scheidereit, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (05) :605-617
[35]   Hostile takeovers:: viral appropriation of the NF-κB pathway [J].
Hiscott, J ;
Kwon, H ;
Génin, P .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (02) :143-151
[36]   MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-κB-dependent proliferative advantage and resistance against FAS-induced cell death in B cells [J].
Ho, L ;
Davis, RE ;
Conne, B ;
Chappuis, R ;
Berczy, M ;
Mhawech, P ;
Staudt, LM ;
Schwaller, J .
BLOOD, 2005, 105 (07) :2891-2899
[37]   Do older adults using NSAIDs have a reduced risk of colorectal cancer? [J].
Hoffmeister, Michael ;
Chang-Claude, Jenny ;
Brenner, Hermann .
DRUGS & AGING, 2006, 23 (06) :513-523
[38]   Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress [J].
Huang, TT ;
Wuerzbrger-Davis, SM ;
Wu, ZH ;
Miyamoto, S .
CELL, 2003, 115 (05) :565-576
[39]   The IKKNF-κB system:: A treasure trove for drug development [J].
Karin, M ;
Yamamoto, Y ;
Wang, QM .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (01) :17-26
[40]   Phosphorylation meets ubiquitination:: The control of NF-κB activity [J].
Karin, M ;
Ben-Neriah, Y .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :621-+